Endra Life Sciences Inc. · NASDAQ:NDRA
Endra Life Sciences — Investor Presentation (June 2017)
19 slides from Endra Life Sciences's investor presentation, Jun 2, 2017
Slide 1: Bringing New Capabilities To Ultrasound
NASDAQ: NDRAU Bringing New Capabilities To dune 1, 2017
Slide 2: Safe Harbor
Safe Harbor NASDAQ: NDRAU Certain statements made in this presentation contain forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the timing of our clinical trials, our strategy, future operations, futur
Slide 3: ENDRA at a Glance
ENDRA at a Glance IPO closed May 12, 2017, with overallotment option fully exercised on May 22, 2017 NASDAQ: NDRAU Key Statistics (as of Ma Symbol (NASDAQ): Common + Warrant (60 days) NDRAU! Symbol (NASDAQ): Common (after 60 days) Shares Outstanding Unit Price Market Capitalization Net Proceeds from
Slide 4: The Medical Imaging Problem
The Medical Imaging Problem Healthcare providers are forced to trade-off between performance, access and safety NASDAQ: NDRAU Conventional CT & MRI ENDRA Ultrasound (like a Data Center) (like a Smart Phone) (like a Flip Phone) Many applications Several advanced applications Limited applications Not
Slide 5: ENDRA's Solution: Thermo Acoustic Enhanced UltraSound (TAEUS™)
ENDRA’s Solution: Thermo Acoustic Enhanced UltraSound (TAEUS™) Bringing distinct new capabilities to ultrasound and broadening access to healthcare NASDAQ: NDRAU Conventional MRI Ultrasound Tissue Temperature 100% Tissue Composition Fat 0% ENDRA
Slide 6: Thermo Acoustic Enhanced UltraSound (TAEUS™) Platform
Thermo Acoustic Enhanced UltraSound (TAEUS™) Platform Multiple potential revenue streams to scale the business Depiction of TAEUS accessory next to ultrasound system ENDRA NASDAQ: NDRAU Software: Multiple new applications enabling ultrasound to visualize tissue composition, function and temperature
Slide 7: ENDRA Technologies
ENDRA Technologies Leveraging IP to pivot ENDRA into the clinical space NASDAQ: NDRAU ENDRA Laboratory System: 2010 ENDRA Clinical System: Expected 2018 Re = Depiction of TAEUS accessory next to ultrasound system Near-infrared light + ultrasound RF pulses + ultrasound World class customers: Stanford
Slide 8: How TAEUS™ Works
How TAEUS™ Works Short RF pulses differentiate tissues in concert with ultrasound =e —-» .) zaeume (E)) MC) Info: Anatomy NA Sonic Waves A (( = »)) Info: Temperature, Composition, etc. Traditional ultrasound and RF energy is absorbed by Sonic waves low energy radio (RF) waves tissues differently bas
Slide 9: Addressable Market For ENDRA's Accessory
Addressable Market For ENDRA’s Accessory Large installed base of diagnostic ultrasound systems" NASDAQ: NDRAU Global Installed Addressable Market? Ultrasound Systems Cart-based non-prenatal systems Out Of Scope 300,000 Addressable Ultrasound Systems x $40K ENDRA Accessory? = $12B Market * Source: Gl
Slide 10: Ultrasound Technology Evolution
Ultrasound Technology Evolution A history of new technologies expanding ultrasound utility and driving M&A activity 2017+ NASDAQ: NDRAU 2000 - 2016 1960 - 2000 a Harmonic imaging Doppler Ultrasound Elastography ore CMUT technology Contrast agents Miniaturization Color Doppler 4D Siemens / Sensant Fu
Slide 11: ENDRA's Initial Focus: Non-Alcoholic Fatty Liver Disease (NAFLD)
ENDRA’s Initial Focus: Non-Alcoholic Fatty Liver Disease (NAFLD) Global health time bomb. TAEUS provides significant diagnostic & monitoring advantages NASDAQ: NDRAU 1.4 Billion people affected globally’ Strong drivers: obesity, diabetes, Hep-C, drugs Often asymptomatic, needs to be monitored Can pr
Slide 12: ENDRA - GE Healthcare Partnership
ENDRA - GE Healthcare Partnership Focused on early diagnosis of Non-Alcoholic Fatty Liver Disease NASDAQ: NDRAU #1 Ultrasound Market Leader April 2017: Renewed collaboration agreement * ENDRA provides GE with 1 year sales exclusivity on TAEUS liver application * GE provides technical advice and GE e
Slide 13: Liver Disease Diagnostic & Therapy Landscape
Liver Disease Diagnostic & Therapy Landscape ENDRA strategically positioned at forefront of growing focus on liver disease NASDAQ: NDRAU NASH (inflammation) FIBROSIS (scarring) Surgical Biopsy Elastography si.sM+PHILI Healthcare 2 2) fe) 4 CO) =< a a Immuren > ie < z Conatus ii E es - ie g z= " GD)
Slide 14: ENDRA Technology Benefits For Key Stakeholders
ENDRA Technology Benefits For Key Stakeholders 6-month payback’ until dedicated reimbursement secured NASDAQ: NDRAU Potential TAEUS Benefits - Short Term Clinician Patient ayer Earlier detection through cost-effective screening v Vv Vv Increased utilization of existing ultrasound, with base of reimb
Slide 15: ENDRA TAEUS™ Liver Application Roadmap
ENDRA TAEUS™ Liver Application Roadmap Estimated timeline for near term clinical data and regulatory clearance NASDAQ: NDRAU TAEUS liver device produced CE clearance Commercialize liver device IPO First IRB* human data Class-lla in Europe | 2017 | | 2018 2019 ED ED SD SE | | | | | Partnership Initia
Slide 16: Board of Directors
Board of Directors Sam Gambhir, MD Michael Harsh Bee Alex Tokman Chair of Radiology at 36-year GE veteran & , CEO Microvision 1 MDB Capital Stanford University retired CTO GE Healthcare Ge-founder of MDB 10+ years at GE Healthcare Management Francois Michelon CEO & Chairman Michael Thornton CTO 15 y
Slide 17: Capitalization Table at May 31, 2017
Capitalization Table at May 31, 2017* Issued & Outstanding | Fully Diluted Common Shares Shares Issued in IPO 1,932,000 25.8% Existing Shareholders 1,700,620 22.7% Management & Directors 255,574 3.4% Common Shares Outstanding 3,888,194 51.9% Warrants & Options Warrants Issued in IPO 2,086,560 27.8%
Slide 18: ENDRA Life Sciences: Investment Summary
ENDRA Life Sciences: Investment Summary @ cc) ®& ENDRA NASDAQ: NDRAU 24 patent assets. World class team: Stanford, GE Healthcare, Weill-Cornell, Smith & Nephew Business model: Scalable platform with licensing, hardware, software, disposables, service $12B addressable market for ENDRA’s $40K accessor
Slide 19: NASDAQ: NDRAU
NASDAQ; NDRAU ENDRA LIFE SCIENCES ENDRA Contact Investor Relations David Wells MZ Group i Contact Us Chief Financial Officer Chris Tyson -0464 Managing Directc drainc.com WWW.ENDRAINC.COM
ENDRA Life Sciences — Investor Presentation (June 2017) on 6ix